The Society for Immunotherapy of Cancer (SITC) hosted Session 103 during the 38th Annual Meeting & Pre-Conference Programs on Friday, November 3, 2023. Available here are the presentation slides and video from “Session 103: Leveraging Tumor-rejecting Leukocytes to Cure Tumors by Immunotherapy” as permitted by presenters.
Carla Rothlin, PhD – Yale School of Medicine
Sjoerd H. van der Burg, PhD – Leiden University Medical Center
The largest component of the tumor immune microenvironment (TME) consists of leukocytes, specifically myeloid cells, which are rapidly recruited from the blood stream and display an enormous functional plasticity driven by a variety of cues. Recent studies clearly showed that the efficacy of T-cell centered immunotherapies can strongly depend on the presence of co-infiltrating tumor-rejecting myeloid cells, including macrophages, neutrophils and/or eosinophils. In addition to the requirement of myeloid cells for effective T-cell based therapy, there are ample examples that point to activation or modulation of myeloid cells to facilitate treatment of cold tumors devoid of CD8+ T cells. This session is purely focused on the tumor-rejecting role of these innate myeloid effector cells and the quick emerging field on how to leverage these innate effectors for tumor control.
To view the entire program schedule (including presenter permission to post) please click here.
SITC 2023 Annual Meeting: Friday, November 302:05:46